Q: we are looking at adding to our position in Well. We purchased at a higher price but it seems to be doing things right. We are looking at 5 years. What are your thoughts.
Q: Hi, I am interested in Life, in particular the dividend and its's sustainability?
How does this etf compare with IHI? Is Life a product you would be interested in owning for income with some growth potential? Thanks
Q: My question is i hold these companies in my rrsp. I am up 186% on msft i have 22 shares and it is 2.8% of my portfolio. WSP i am up 195% 62 shares and it is 3.98% of my portfolio and unh i am up 135% 11 shares and is 2.69% of my portfolio. I would like to sell 5 shares of unh, 7 shares of msft and 12 shares of wsp. What companies should i pick up after selling these i have about 3 year time frame, or should i just hold on to them all. Thank you
Q: An article today suggested that Apple is close to coming out with a diabetic monitoring capability for its iWatch. If correct, what would that do to DXCM?
With that question in mind, I'm looking to add a small position in healthcare. Which of the listed companies do you see as having a better future for a long-term hold?
Q: I have HHL & HHL.U in my registered accounts for many years. It has been a good dividend (>8%) generator with its policy of options investment of about 30%. It has a high management fee of 0.85 and MER of 0.99.
LIFE is similar with almost half fee and dividend is equally attractive. Like to get your advise comparable merits of switching HHL to LIFE.
Q: I have the above but am thinking of selling and buying into a drug etf. I am open to expanding one or two drug co.to accompany lly but I am looking for your comments and advice. Take whatever points for this info.
Do you have an opinion on Biden comments re the pharma and also basic materials on how or will that effect canada and which s tks could be adversely challenged. Thank you.
Q: It looks like LNTH’s fortunes changed fairly dramatically on or about Feb. 24th 2022. At the time there were two press releases; Feb. 23rd re: FDA approval of new manufacturing facility, and Feb. 24th Q4 and full year 2021 Financial Results. Do you know which precipitated the sharp rise in share price, or was it a combination of both? Just trying to figure out exactly what the market might have loved so much at the time, and if you think it is still proving out? Thank you for any insight you might have.
Considering the recent rise of VMD share value, would you endorse a switch to the other former PHM spinout, QIPT. How do you rank them in comparison? I see that you are feeling more confident about VMD recently, but recognize that it's considerably more expensive. Thanks, Brad
Q: I would like to add to my CDR holdings of either PFE, ABBV or UNH. I am leaning towards PFE since it's price has been down lately and it has a decent yield. How are CDR distributions treated for tax purposes, are they considered to be Canadian or US equities?
Thank you.
Q: This question concerns Healthcare in a well-diversified Canadian portfolio (~30 holdings), focused slightly toward growth. Our target is for a 5% weight in this sector.
Currently, we only hold CSH.UN at a loss. We are open to selling it outright and replacing it with 1 or more of your favourites or topping it up and adding at least 1 growth-oriented suggestion. I understand from a previous question that CSH.UN has performed in a close range with REITs, which have adequate representation in our portfolio.
What would be your top picks in Healthcare for long term holds (5+ years)? How would you rate them (1-10, 10 being best) for new money today?
How would you proceed? Would you suggest going with 1 or 2 names? Would you suggest topping up CSH.UN and adding a 2nd name, selling CSH.UN and adding 1 or 2 new names, etc?